A Study of LY3556050 in Adult Participants With Diabetic Peripheral Neuropathic Pain

Completed · Phase 2 · Has a placebo group

Conditions studied: Diabetic Peripheral Neuropathy

In brief

The main purpose of this study is to determine the safety and efficacy of LY3556050 versus placebo in participants with diabetic peripheral neuropathic pain (DPNP). The study will lasts approximately 24 weeks, across 3 study periods.

Key facts

Study ID

NCT06074562

Run by

Eli Lilly and Company

People needed

404

Starts

2023-10-05

Expected to finish

2025-06-11

Last updated by the study team

2026-07-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have a history and current diagnosis of Type 1 Diabetes (T1D) or Type 2 Diabetes (T2D) diagnosed for at least 6 months prior to screening.
• Have a stable glycemic control on stable diabetes treatment regimen for at least 90 days prior to day 1 with a hemoglobin A1c (HbA1c) ≤10 for T1D and HbA1c ≤11 for participants with T2D at time of screening.
• Have a history of daily peripheral neuropathic pain for at least 12 weeks based on participant report or medical history.
• Have a visual analog scale (VAS) pain value ≥40 and <95 during screening.
• Have presence of diabetic peripheral neuropathy of symmetrical nature and in lower extremities for ≥6 months and diagnosed by a score of Part B ≥3 on Michigan Neuropathy Screening Instrument
• Are willing to maintain a consistent regimen of any ongoing nonpharmacologic pain-relieving therapies (for example, physical therapy) and will not start any new nonpharmacologic pain-relieving therapies during study participation.
• Are willing to discontinue all medications taken for chronic pain conditions, except allowed concomitant pain medication permitted per protocol, for the duration of the study
• Have a body mass index ≤45 kilogram/square meter (kg/m²) (inclusive).
• Are men, or women able to abide by reproductive and contraceptive requirements.

You may not qualify if…

• History of other potentially causative and/or confounding sources of pain that may impair self-assessment of pain due to DPNP.
• Have had a procedure within the past 6 months intended to produce permanent sensory loss in the target area of interest (for example, ablation techniques.
• Have had cancer within 2 years of baseline, except for cutaneous basal cell or squamous cell carcinoma resolved by excision.
• Are, in the judgment of the investigator, actively suicidal and therefore deemed to be at significant risk for suicide.
• Have in the judgement of the investigator, an acute, serious, or unstable medical condition or a history or presence of any other medical illness that would preclude study participation.
• Have a positive HIV test result at screening.
• Have a surgery planned during the study for any reason.
• Have a substance use disorder as defined by the Diagnostic and Statistical Manual of Mental Disorders (5th edition; DSM-5; American Psychiatric Association)

Where it is running

• Headlands Research - Scottsdale — Scottsdale, Arizona, United States
• Orange Grove Family Practice — Tucson, Arizona, United States
• Preferred Research Partners — Little Rock, Arkansas, United States
• Hope Clinical Research, Inc. — Canoga Park, California, United States
• Valley Clinical Trials, Inc. — Northridge, California, United States
• Northern California Research - Sacramento — Sacramento, California, United States
• CMR of Greater New Haven, LLC — Hamden, Connecticut, United States
• Suncoast Research Group — Miami, Florida, United States
• New Horizon Research Center — Miami, Florida, United States
• Northwestern University — Chicago, Illinois, United States
• Alliance for Multispecialty Research, LLC — Wichita, Kansas, United States
• Alliance for Multispecialty Research, LLC — Lexington, Kentucky, United States
• Care Access - Lake Charles — Lake Charles, Louisiana, United States
• MedVadis Research Corporation — Waltham, Massachusetts, United States
• SKY Integrative Medical Center/SKYCRNG — Ridgeland, Mississippi, United States
• StudyMetrix Research — City of Saint Peters, Missouri, United States
• Alliance for Multispecialty Research, LLC — Kansas City, Missouri, United States
• Clinvest Research LLC — Springfield, Missouri, United States
• Las Vegas Medical Research — Las Vegas, Nevada, United States
• UniMed Center — East Brunswick, New Jersey, United States
• North Suffolk Neurology — Port Jefferson Station, New York, United States
• Lucas Research - Hickory — Hickory, North Carolina, United States
• Lucas Research, Inc — Morehead City, North Carolina, United States
• Velocity Clinical Research, Medford — Medford, Oregon, United States
• The Institute for Liver Health II dba Arizona Clinical Trials - Mesa — Chandler, Arizona, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.